Quick answer: For Medicare CPAP coverage, the four-hour rule helps determine continued payment for equipment. It does not establish how much treatment is enough for every person or every health outcome. Research measures sleepiness, daily functioning, and cardiovascular events separately. Meeting an insurance threshold cannot guarantee all three benefits. Check your coverage paperwork and your clinical progress as two separate tasks. CMS coverage criteria; American Thoracic Society policy statement.
Written and edited by: Denny Jaeyong Choi (JD), INSEAD MBA.
Published: September 17, 2026 · Last editorial review: September 17, 2026 · Policy and evidence checked: September 17, 2026.
You finally get comfortable with the mask. The app shows a qualifying night. Then a reasonable question appears: if the insurer counts four hours as a success, can you take the mask off after that?
That question sits between two systems with different jobs. An insurer needs a payment rule. A sleep clinician needs to know whether treatment is addressing your breathing and symptoms. This review explains the U.S. coverage process, then examines what research can—and cannot—tell us about hours of use.
What to take away
- Check the required usage window and follow-up appointment with your supplier at setup.
- Measure how you feel as well as what the machine records.
- Read a study’s population, comparison, and outcome before turning its result into a personal treatment target.
- Ask for help with uncomfortable treatment early; an insurance milestone alone does not resolve the underlying problem.
What Medicare CPAP coverage actually requires
CPAP delivers air pressure through a mask to keep the upper airway open. Original Medicare may cover it for obstructive sleep apnea after a clinical evaluation and a qualifying laboratory or home sleep test. National criteria include an apnea–hypopnea index (AHI) or respiratory disturbance index (RDI) of at least 15, or 5–14 with specified symptoms or conditions. Initial coverage is a 12-week trial. These are coverage criteria; interpretation belongs with the treating clinician. CMS NCD 240.4.
For continued coverage, LCD L33718 specifies use for at least four hours per night on 70% of nights during a consecutive 30-day period within the first three months. It also requires clinical re-evaluation between days 31 and 91, with documented symptom improvement and review of objective adherence data. The current displayed revision took effect January 1, 2024; “2026” here identifies our check date, not a newly introduced rule.
A worked example: 70% of 30 nights is 21 nights. Twenty nights of six hours each produce more total hours than 21 nights of four hours each, but they meet different nightly-count thresholds. This arithmetic illustrates why an average-hours display alone can be misleading. Ask the supplier to show the qualifying window in its report.
Medicare CPAP coverage costs: what you may pay
Under Original Medicare, CPAP is a Part B durable-medical-equipment benefit. If the supplier accepts assignment, you generally pay 20% of the Medicare-approved amount after the Part B deductible. Medicare normally makes rental payments for 13 continuous months before you own the machine. Masks and tubing can have separate charges. Supplier participation, other insurance, and your deductible affect your bill. Medicare.gov cost and rental rules.
For example, if a covered rental month had a $100 approved amount and the deductible were already met, 20% would be $20 before supplemental insurance. This is an illustration, not a quoted CPAP price. Request your actual approved amount and responsibility in writing.
Medicare Advantage can have different cost sharing, networks, and authorization procedures. Confirm the supplier and approval process with your plan before accepting equipment. Medicare coverage comparison. If diagnosis is still pending, see our home versus laboratory sleep-test cost guide.
What studies show about hours of CPAP use
The three publications below address different questions. They are selected to explain a common interpretation problem, not to represent every CPAP study. In particular, a study relating use to symptoms and a trial counting heart attacks or strokes cannot answer each other’s questions.
| Publication | Who and how long? | Comparison and result | What limits the conclusion? |
|---|---|---|---|
| Weaver et al., 2007 Multicenter, quasi-experimental study | 149 adults with severe OSA; 85–120 analyzed depending on outcome; 3 months. | Compared recorded use with changes in symptoms and function. Estimated response thresholds differed: about 4 hours for self-reported sleepiness, 6 for objectively measured sleepiness, and 7.5 for daily functioning. | Participants were not randomized to different nightly durations. These model estimates are neither guaranteed personal targets nor proof of a universal minimum. |
| SAVE, 2016 Randomized trial | 2,717 adults aged 45–75 with moderate-to-severe OSA and established cardiovascular disease; mean follow-up 3.7 years. | CPAP plus usual care versus usual care. Cardiovascular composite events: 17.0% versus 15.4%; hazard ratio 1.10 (95% CI 0.91–1.32). Mean CPAP use: 3.3 hours/night. | No statistically clear cardiovascular benefit from assignment to CPAP. Mostly men with minimal sleepiness; this does not directly test consistent full-night use or every OSA population. |
| Sánchez-de-la-Torre et al., 2023 Individual-participant-data meta-analysis | 4,186 participants from SAVE, ISAACC, and RICCADSA; mean follow-up 3.25 years; existing cardiovascular disease. | Randomized-group analysis: hazard ratio 1.01 (95% CI 0.87–1.17). Adjusted analysis of adherent use, at least 4 hours/day: 0.69 (0.52–0.92) for recurrent major cardiac/cerebrovascular events. | Actual adherence was not randomized; unmeasured differences may remain despite adjustment. SAVE is included, so these are not independent patient groups to add together. |
OSA = obstructive sleep apnea. A hazard ratio describes relative event rates over follow-up; a value of 1 indicates no difference. Confidence intervals show statistical uncertainty, not the full extent of possible bias.
Why the results can seem contradictory
Different outcomes need different evidence
Weaver’s findings suggest that the relationship between nightly use and improvement depends on what is measured. Feeling less sleepy and returning to normal everyday functioning were separate outcomes. The study did not measure prevention of heart attacks, diabetes, or death. Its different thresholds should prompt better questions about treatment response rather than a new universal stopping time.
SAVE, meanwhile, tested a cardiovascular composite. Its neutral primary result coexisted with improvements in sleepiness and quality of life. A negative result for one outcome does not cancel every other benefit, and symptom improvement does not prove cardiovascular protection. SAVE report.
Being assigned treatment differs from using it consistently
The 2023 analysis found different answers when comparing randomized groups and examining actual adherence. The latter result supports further attention to sustained use, but cannot establish that crossing four hours itself causes a 31% reduction in cardiovascular risk. Adherence may track unmeasured health behaviors or circumstances. It also does not validate Medicare’s particular 30-day window. JAMA analysis and limitations.
An expert proposal does not change an insurer’s rule
The American Thoracic Society’s 2023 statement questioned the scientific basis of a rigid four-hour/70% threshold and recommended policy changes. It describes improvements below and above the cutoff and barriers that can make adherence harder. This is a professional policy statement, not a trial establishing a replacement target—and a recommendation to reform coverage is not evidence that CMS has adopted it. ATS statement.
How much applies to a U.S. Medicare reader?
The payment rules directly address U.S. coverage. The clinical evidence has a narrower fit. Weaver studied severe OSA at U.S. and Canadian centers. SAVE and the pooled cardiovascular analysis studied people who already had cardiovascular disease and included many adults younger than the typical age-based Medicare beneficiary. They do not directly establish effects in a frail older adult, a newly diagnosed person without cardiovascular disease, or someone whose main problem is severe daytime sleepiness.
None of these comparisons randomized people to 3 hours 59 minutes versus 4 hours, or to meeting versus missing Medicare’s exact monthly pattern. There is therefore no basis here to interpret one minute across the coverage boundary as a sudden biological change. That is an inference about the studies’ designs, not a newly calculated treatment effect.
Medicare CPAP coverage checklist: track treatment response
| When | Coverage question | Clinical question |
|---|---|---|
| At setup | What is my recorded start date, and who schedules follow-up? | Who helps with leaks, dryness, or an uncomfortable mask? |
| Early follow-up | Can you show my qualifying usage window? | Are the pressure, mask fit, and remaining breathing events being reviewed? |
| Before the deadline | Has the clinic received the usage report and completed the required documentation? | Have my symptoms improved, and what still needs attention? |
| After approval | What rental and supply costs should I expect? | What is my ongoing treatment goal and reassessment plan? |
This checklist is our practical translation of the coverage process; it is not a validated intervention. Keep the prescription, sleep report, setup date, supplier details, and appointment confirmation together. Note specific difficulties and when they happen, so the next conversation can focus on a fix.
“Please show me whether my report satisfies the insurance window. Separately, is my treatment working well enough, and what should I change with your guidance if I still feel unwell?”
Feeling comfortable enough to use PAP throughout sleep is a more useful clinical discussion than planning to stop once an app shows a qualifying night. Do not change pressure settings or discontinue prescribed treatment based on this review. The ATS statement supports individualized goals and attention to barriers; your treating team must apply that to your situation.
If paperwork or the trial goes wrong
A late follow-up and a failed trial have different consequences. Under L33718, documented benefit and adherence at a delayed re-evaluation can restart coverage from that date. Re-qualification after a failed trial generally requires clinical re-evaluation and a repeat facility-based Type I sleep test. Ask which situation applies. CMS continued-coverage and re-qualification rules.
Request the written reason for any denial. Ask whether the missing item is the original sleep report, an order, follow-up documentation, or something else. CMS identifies incomplete documentation as an important payment problem. CMS documentation guidance. For a coverage disagreement, use the instructions and deadlines in the notice; Medicare explains the appeal routes.
Medicare CPAP coverage: common questions
Does passing the rule mean my sleep apnea is controlled?
It documents a pattern of use. Ask the clinician to assess symptoms, remaining breathing events, and treatment quality as well. The comparisons above explain why a single usage number cannot answer every outcome question.
Does the negative cardiovascular trial mean I should stop CPAP?
No. A population-level result for a specific outcome cannot decide your treatment. Review your diagnosis, symptoms, response, and treatment goals with the prescribing clinician.
Will Medicare replace a worn-out machine?
CMS distinguishes replacement after the five-year reasonable useful lifetime from loss, theft, or irreparable damage during it. After five years, the treating practitioner must document ongoing use and benefit at an in-person evaluation; a new sleep test or trial is not required under that replacement rule. CMS replacement guidance.
Can weight-loss medication change my CPAP coverage route?
Medication coverage and equipment coverage need separate checks. Our Medicare GLP-1 coverage guide explains the medication pathways. A change in weight or symptoms should be discussed with the sleep clinician before altering PAP treatment.
What Medicare CPAP coverage cannot tell you
These sources do not identify one optimal nightly duration for every patient, prove that Medicare’s threshold is the best coverage policy, or establish cardiovascular protection for everyone who meets it. The useful conclusion is specific: check the administrative requirements carefully, then judge treatment against the health outcomes that matter to the individual.
How this review was prepared
Type and question: A focused narrative evidence and policy review asking whether a CPAP insurance adherence threshold can stand in for clinical benefit. This article is not an original systematic review, meta-analysis, or clinical guideline.
Search: On September 17, 2026, targeted web searches covered Medicare.gov, CMS coverage documents, PubMed/PMC records, and journal pages. Queries included “Medicare CPAP coverage,” “CPAP four-hour adherence threshold,” “Weaver CPAP hours daily functioning,” “SAVE CPAP cardiovascular events,” and “CPAP adherence individual participant meta-analysis.” Selection favored directly applicable official policy and publications that distinguish outcomes or study designs. This was not an exhaustive database search or an attempt to identify every recent trial.
Access and checks: We checked the CMS and Medicare pages, the accessible ATS text, SAVE’s abstract and accessible report text, and the JAMA results and limitations. Weaver’s numeric details were checked against its indexed abstract; direct PubMed/PMC retrieval encountered an access challenge, so a complete full-text appraisal of that study was not performed. Figures shown above reproduce reported estimates; we did not recalculate their models. SAVE’s inclusion in the 2023 analysis was checked explicitly.
Limits: No prespecified protocol, independent duplicate screening, formal risk-of-bias scoring, GRADE assessment, or new statistical pooling was conducted. Studies may have been missed. We did not inspect an individual insurance contract or verify benefits with a supplier. This review cannot certify that a particular claim will be paid.
Editorial review: AI assisted with source finding, comparison, and drafting. Denny Jaeyong Choi (JD) completed the editorial review of this version before publication. Editorial review is not independent journal peer review. Learn more about our editorial policy.
Revision record
September 17, 2026 — first published version: Developed the initial coverage guide into an outcome-specific evidence review. Added the research comparison, separated adherence associations from randomized treatment effects, disclosed overlapping participants, linked claims at their point of use, and clarified the distinction between late follow-up and trial failure.
When to revisit: A change to NCD 240.4 or LCD L33718, a relevant new trial, a correction to an included paper, or a material reader-reported error should trigger reassessment. A future update should identify exactly which claim changed and why.
Source register
- Medicare.gov: CPAP therapy — benefit, rental, assignment, and cost sharing.
- CMS NCD 240.4 — national diagnostic and initial-coverage criteria.
- CMS LCD L33718 — adherence, follow-up, and re-qualification.
- CMS: CPAP devices and accessories — documentation and replacement guidance.
- ATS policy statement, 2023. DOI: 10.1164/rccm.202210-1846ST — policy critique, not a clinical trial.
- Weaver et al., Sleep, 2007;30:711–719. DOI: 10.1093/sleep/30.6.711 — hours of use, sleepiness, and function.
- McEvoy et al., NEJM, 2016;375:919–931. DOI: 10.1056/NEJMoa1606599 — SAVE randomized trial.
- Sánchez-de-la-Torre et al., JAMA, 2023;330:1255–1265. DOI: 10.1001/jama.2023.17465 — individual-participant-data meta-analysis.
This article provides general health education and an explanation of insurance rules. It does not replace individual medical advice or a plan’s coverage determination. Confirm current requirements with your clinician, supplier, and insurer.